Complexity of tumor vasculature in clear cell renal cell carcinoma

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2282-2289

  Qian, Chao Nan ^a,b,c   Huang, Dan ^b   Wondergem, Bill ^b   Teh, Bin Tean ^b,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Angiogenesis; Clear cell renal cell carcinoma; Endothelial cells; Pericyte; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; GADOLINIUM PENTETATE MEGLUMINE; MESSENGER RNA; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; KIDNEY CARCINOMA; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROGNOSIS; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65949096075     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24238     Document Type: Conference Paper

References (62)

1. Ferda J, Hora M, Hes O, Ferdova E, Kreuzberg B. Assessment of the kidney tumor vascular supply by 2-phase MDCT-angiography. Eur J Radiol. 2007;62:295-301.
2. Anderson H, Yap JT, Wells P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer. 2003;89:262-267. (Pubitemid 36976313)
3. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22:6810-6818. (Pubitemid 37372221)
4. Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, Resnick MB. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res. 2001;7:533-537.
5. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007;27:1125-1144.
6. Huang D, Ding Y, Luo WM, et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 2008;68:81-88.
7. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
8. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 2002;86:1566-1577.
9. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002;100:3344-3351. (Pubitemid 35217086)
10. Niemoller K, Jakob C, Heider U, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol. 2003;129:234-238. (Pubitemid 36713799)
11. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644. (Pubitemid 30210544)
12. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23:162-169.
13. Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004;34:235-239. (Pubitemid 39136830)
14. Anastassiou G, Duensing S, Steinhoff G, et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma. Oncology. 1996;53:127-132.
15. Baldewijns MM, Thijssen VL, Van den Eynden GG, et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer. 2007;96:1888-1895. (Pubitemid 46912016)
16. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol. 1997;80:401-404.
17. Imao T, Egawa M, Takashima H, Koshida K, Namiki M. Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma. Int J Urol. 2004;11:948-953.
18. Mertz KD, Demichelis F, Kim R, et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol. 2007;38:1454-1462. (Pubitemid 47418973)
19. Rioux-Leclercq N, Epstein JI, Bansard JY, et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol. 2001;32:1209-1215.
20. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int. 2006;97:706-710.
21. Yagasaki H, Kawata N, Takimoto Y, Nemoto N. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol. 2003;10:220-227.
22. Yildiz E, Ayan S, Goze F, Gokce G, Gultekin EY. Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma. BJU Int. 2008;101:758-764.
23. Fukata S, Inoue K, Kamada M, et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer. 2005;103:931-942. (Pubitemid 40270069)
24. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2004;93:291-296.
25. Kavantzas N, Paraskevakou H, Tseleni-Balafouta S, et al. Association between microvessel density and histologic grade in renal cell carcinomas. Pathol Oncol Res. 2007;13:145-148. (Pubitemid 47204737)
26. Nativ O, Sabo E, Reiss A, Wald M, Madjar S, Moskovitz B. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology. 1998;51:693-696.
27. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol. 1995;2:156-160.
28. Zhang X, Yamashita M, Uetsuki H, Kakehi Y. Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol. 2002;9:509-514.
29. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer. 1997;80:1768-1775. (Pubitemid 27475935)
30. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology. 1995;46:27-30.
31. Minardi D, Lucarini G, Mazzucchelli R, et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol. 2005;174(4 pt 1):1208-1212. (Pubitemid 41318683)
32. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol. 2007;28:158-164.
33. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002;196:186-193.
34. Yao X, Qian CN, Zhang ZF, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res. 2007;13:161-169. (Pubitemid 46121865)
35. Okuhata Y, Brasch RC, Pham CD, et al. Tumor blood volume assays using contrast-enhanced magnetic resonance imaging: regional heterogeneity and postmortem artifacts. J Magn Reson Imaging. 1999;9:685-690.
36. Yabuki T, Togami I, Kitagawa T, et al. MR imaging of renal cell carcinoma: associations among signal intensity, tumor enhancement, and pathologic findings. Acta Med Okayama. 2003;57:179-186.
37. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-1393.
38. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
39. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242-245.
40. Yonenaga Y, Mori A, Onodera H, et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology. 2005;69:159-166. (Pubitemid 41376915)
41. Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005;103:2517-2525. (Pubitemid 40800530)
42. Coons BJ, Stec AA, Stratton KL, et al. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009;27:75-79.
43. Pflanz S, Brookman-Amissah S, Roigas J, Kendel F, Hoschke B, May M. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma. Scand J Urol Nephrol. 2008;42:507-513.
44. Ficarra V, Novara G, Galfano A, et al. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. In press.
45. Minervini A, Di Cristofano C, Gacci M, et al. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. J Urol. 2008;180:1284-1289.
46. Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, Thelen P. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch. 2001;439:645-652.
47. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18:5356-5362.
48. Qian CN, Berghuis B, Tsarfaty G, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006;66:10365-10376.
49. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res. 2000;60:55-69.
50. Gonul E, Duz B, Kahraman S, Kayali H, Kubar A, Timurkaynak E. Early pericyte response to brain hypoxia in cats: an ultrastructural study. Microvasc Res. 2002;64:116-119.
51. Israely T, Dafni H, Granot D, Nevo N, Tsafriri A, Neeman M. Vascular remodeling and angiogenesis in ectopic ovarian transplants: a crucial role of pericytes and vascular smooth muscle cells in maintenance of ovarian grafts. Biol Reprod. 2003;68:2055-2064.
52. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst. 1989;81:497-502.
53. Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol. 2007;38:1489-1495.
54. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int. 2006;98:661-667.
55. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998;22:200-209.
56. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol. 1999;115:176-182. (Pubitemid 29030382)
57. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
58. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor- 2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141:1659-1673.
59. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol. 2003;162:183-193.
60. Lu C, Sood A. Role of pericytes in angiogenesis. In: Teicher BA, Ellis LM, eds. Angiogenesis Agents in Cancer Therapy. 2nd ed. Totowa, NJ: Humana Press, Inc; 2008:117-132.
61. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008;68:8066-8075.
62. Lu C, Thaker PH, Lin YG, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008;198:477.e1-9; discussion 477.e9-10